Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Primary Progressive Multiple Sclerosis (PPMS) Overview 6 Therapeutics Development 7 Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 7 Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 8 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 11 Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 12 AB Science SA 12 F. Hoffmann-La Roche Ltd. 13 Genzyme Corporation 14 Kyorin Pharmaceutical Co., Ltd. 15 MedDay 16 Santhera Pharmaceuticals Holding AG 17 Teva Pharmaceutical Industries Limited 18 Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ApE - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 biotin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GZ-402668 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ibudilast - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 idebenone - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 laquinimod sodium - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 masitinib - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ocrelizumab - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Stem Cell Therapy for CNS Disorders - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Primary Progressive Multiple Sclerosis (PPMS) - Recent Pipeline Updates 50 Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects 79 Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 80 Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 81 Featured News & Press Releases 81 Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 81 Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 81 Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 83 Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 84 Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 85 Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 85 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88

List of Tables Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H1 2016 12 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 13 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H1 2016 14 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 15 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay, H1 2016 16 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 17 Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Primary Progressive Multiple Sclerosis (PPMS) Therapeutics - Recent Pipeline Updates, H1 2016 50 Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H1 2016 79 Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H1 2016 80 List of Figures Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Top 10 Targets, H1 2016 20 Number of Products by Stage and Top 10 Targets, H1 2016 20 Number of Products by Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26

AB Science SA F. Hoffmann-La Roche Ltd. Genzyme Corporation Kyorin Pharmaceutical Co., Ltd. MedDay Santhera Pharmaceuticals Holding AG Teva Pharmaceutical Industries Limited